With Positive Boceprevir Data In Hand, Merck Prepares NDA Submission
Two Phase III trials evaluating the protease inhibitor in HCV met their primary endpoints but the real test is how boceprevir stacks up to Vertex's telaprevir.
Two Phase III trials evaluating the protease inhibitor in HCV met their primary endpoints but the real test is how boceprevir stacks up to Vertex's telaprevir.